14 global firms choose GVK Bio for clinical services

Drug discovery research and development organisation GVK Biosciences has been selected as a preferred provider to a consortium of 14 global Product Development Partners (PDPs) for clinical services in Asia.

"GVK Biosciences (GVK BIO) is extremely pleased to support the development of health solutions for neglected infectious diseases in India.

"We are excited to partner the PDPs in advancing their clinical programs and help address medical and health problems of millions globally," GVK BIO Chief Executive Officer Manni Kantipudi said.

GVK BIO will collaborate with the consortium as a niche service provider for clinical monitoring, logistics support and safety monitoring apart from overall project management.

The PDPs, funded in-part by the Bill and Melinda Gates Foundation are not-for-profit entities focused on developing new interventions for diseases that are often neglected by mainstream pharmaceutical and bio-tech companies, such as tuberculosis, malaria, kala-azar, HIV/AIDS, childhood pneumonia, and diarrhoeal diseases.

Collectively the 14 PDPs anticipate funding 85 clinical trials in the developing world over the next two years and India features as a key developing world country, a GVK BIO release said here today.

GVK BIO is currently working with some of the PDPs and collaborating with investigators and public institutions in India and Bangladesh to help develop preventive and therapeutic modalities that can be introduced into public health programs with the aim of dramatically reducing the social and economic burden of these diseases.